{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:28:17Z","timestamp":1704846497981},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00108-023-01640-9","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T11:02:34Z","timestamp":1702897354000},"page":"79-85","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nach der COVID-19-Pandemie\u00a0\u2013 welche neuen Impfungen im Erwachsenenalter sind schon oder bald verf\u00fcgbar?","After the COVID-19 pandemic\u2014Which new vaccinations for adults are available or coming soon?"],"prefix":"10.1007","volume":"65","author":[{"given":"A.","family":"Kwetkat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Leischker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-S.","family":"Endres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"17","key":"1640_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s15006-023-2844-9","volume":"165","author":"A Kwetkat","year":"2023","unstructured":"Kwetkat\u00a0A et\u00a0al (2023) Seasonal vaccinations in old age: influenza and co. MMW Fortschr Med 165(17):42\u201345","journal-title":"MMW Fortschr Med"},{"issue":"6","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"e0253118","DOI":"10.1371\/journal.pone.0253118","volume":"16","author":"C Theilacker","year":"2021","unstructured":"Theilacker\u00a0C et\u00a0al (2021) Population-based incidence and mortality of community-acquired pneumonia in Germany. PLoS ONE 16(6):e253118","journal-title":"PLoS ONE"},{"key":"1640_CR3","unstructured":"STIKO (2023) Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen \u2265\u202f60\u00a0Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken. Epid Bull (39):3\u201344"},{"issue":"3","key":"1640_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink\u00a0B et\u00a0al (2022) Pivotal phase\u00a03 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u3009\/=18 years. Clin Infect Dis 75(3):390\u2013398","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1640_CR5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14760584.2023.2262575","volume":"22","author":"F Kuhne","year":"2023","unstructured":"Kuhne\u00a0F et\u00a0al (2023) Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines 22(1):921\u2013932","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"1640_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.vaccine.2022.11.046","volume":"41","author":"K Cannon","year":"2023","unstructured":"Cannon\u00a0K et\u00a0al (2023) Safety and immunogenicity of a\u00a020-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A\u00a0phase\u00a03 randomized trial. Vaccine 41(13):2137\u20132146","journal-title":"Vaccine"},{"issue":"49","key":"1640_CR7","first-page":"3","volume":"2022","author":"T Rieck","year":"2022","unstructured":"Rieck\u00a0T, Steffen\u00a0A, Feig\u00a0M, Siedler\u00a0A (2022) Impfquoten bei Erwachsenen in Deutschland \u2013 Aktuelles aus der KV-Impfsurveillance. Epidemiol Bull 2022(49):3\u201323","journal-title":"Epidemiol Bull"},{"key":"1640_CR8","doi-asserted-by":"publisher","unstructured":"Graham BS, Modjarrad K, McLellan JS (2015) Novel antigens for RSV vaccines. Review Curr Opin Immunol 35:30\u20138. https:\/\/doi.org\/10.1016\/j.coi.2015.04.005","DOI":"10.1016\/j.coi.2015.04.005"},{"issue":"1","key":"1640_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","volume":"38","author":"EE Walsh","year":"2017","unstructured":"Walsh\u00a0EE (2017) Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med 38(1):29\u201336","journal-title":"Clin Chest Med"},{"issue":"6","key":"1640_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/ciab595","volume":"74","author":"AR Branche","year":"2022","unstructured":"Branche\u00a0AR et\u00a0al (2022) Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020. Clin Infect Dis 74(6):1004\u20131011","journal-title":"Clin Infect Dis"},{"key":"1640_CR11","doi-asserted-by":"publisher","first-page":"105399","DOI":"10.1016\/j.jcv.2023.105399","volume":"161","author":"A Ambrosch","year":"2023","unstructured":"Ambrosch\u00a0A et\u00a0al (2023) Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: risk factors, symptomatology and clinical course compared to influenza A \/ B and the original SARS-CoV\u20112 strain. J\u00a0Clin Virol 161:105399","journal-title":"J Clin Virol"},{"issue":"16","key":"1640_CR12","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh\u00a0EE et\u00a0al (2023) Efficacy and safety of a\u00a0bivalent RSV prefusion F vaccine in older adults. N\u00a0Engl J Med 388(16):1465\u20131477","journal-title":"N Engl J Med"},{"issue":"16","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann\u00a0B et\u00a0al (2023) Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N\u00a0Engl J Med 388(16):1451\u20131464","journal-title":"N Engl J Med"},{"issue":"7","key":"1640_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi\u00a0A et\u00a0al (2023) Respiratory syncytial virus prefusion F protein vaccine in older adults. N\u00a0Engl J Med 388(7):595\u2013608","journal-title":"N Engl J Med"},{"key":"1640_CR15","doi-asserted-by":"publisher","first-page":"677907","DOI":"10.3389\/fragi.2021.677907","volume":"2","author":"F Ecarnot","year":"2021","unstructured":"Ecarnot\u00a0F et\u00a0al (2021) Vaccines and senior travellers. Front Aging 2:677907","journal-title":"Front Aging"},{"issue":"1","key":"1640_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/cid\/ciab864","volume":"75","author":"L Rivera","year":"2022","unstructured":"Rivera\u00a0L et\u00a0al (2022) Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003). Clin Infect Dis 75(1):107\u2013117","journal-title":"Clin Infect Dis"},{"issue":"10234","key":"1640_CR17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","volume":"395","author":"S Biswal","year":"2020","unstructured":"Biswal\u00a0S et\u00a0al (2020) Efficacy of a\u00a0tetravalent dengue vaccine in healthy children aged 4\u201316\u00a0years: a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 395(10234):1423\u20131433","journal-title":"Lancet"},{"issue":"9","key":"1640_CR18","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","volume":"225","author":"E Lopez-Medina","year":"2022","unstructured":"Lopez-Medina\u00a0E et\u00a0al (2022) Efficacy of a\u00a0dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination. J\u00a0Infect Dis 225(9):1521\u20131532","journal-title":"J Infect Dis"},{"key":"1640_CR19","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.tmaid.2023.102598","volume":"54","author":"M Angelin","year":"2023","unstructured":"Angelin\u00a0M et\u00a0al (2023) Qdenga(R)\u2014A promising dengue fever vaccine; can it be recommended to non-immune travelers? Travel Med Infect Dis 54:102598","journal-title":"Travel Med Infect Dis"},{"issue":"43","key":"1640_CR20","first-page":"3","volume":"2023","author":"KK-S Kling","year":"2023","unstructured":"Kling\u00a0KK\u2011S, Schmidt-Chanasit\u00a0J, Stratil\u00a0J, Bogdan\u00a0C, Ramharter\u00a0M, Rieke\u00a0B, Wichmann\u00a0O, Burchard\u00a0G (2023) STIKO-Empfehlung und wissenschaftliche Begr\u00fcndung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga. Epidemiol Bull 2023(43):3\u201343","journal-title":"Epidemiol. Bull."},{"issue":"2","key":"1640_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","volume":"23","author":"H Platt","year":"2023","unstructured":"Platt\u00a0H et\u00a0al (2023) Safety, tolerability, and immunogenicity of a\u00a021-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase\u00a01\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis 23(2):233\u2013246","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1640_CR22","doi-asserted-by":"publisher","first-page":"2117949","DOI":"10.1080\/21645515.2022.2117949","volume":"18","author":"A Datta","year":"2022","unstructured":"Datta\u00a0A et\u00a0al (2022) Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production. Hum Vaccin Immunother 18(4):2117949","journal-title":"Hum Vaccin Immunother"},{"issue":"31","key":"1640_CR23","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","volume":"40","author":"GR Chichili","year":"2022","unstructured":"Chichili\u00a0GR et\u00a0al (2022) Phase\u00a01\/2\u00a0study of a\u00a0novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64\u00a0years and in older adults aged 65 to 85\u00a0years. Vaccine 40(31):4190\u20134198","journal-title":"Vaccine"},{"issue":"23","key":"1640_CR24","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1016\/j.vaccine.2021.03.070","volume":"39","author":"J Fairman","year":"2021","unstructured":"Fairman\u00a0J et\u00a0al (2021) Non-clinical immunological comparison of a\u00a0Next-Generation\u00a024-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Vaccine 39(23):3197\u20133206","journal-title":"Vaccine"},{"key":"1640_CR25","doi-asserted-by":"crossref","unstructured":"Wang WC et\u00a0al (2022) Progress towards the development of a\u00a0universal influenza vaccine. Viruses 14(8)","DOI":"10.3390\/v14081684"},{"key":"1640_CR26","doi-asserted-by":"publisher","first-page":"105505","DOI":"10.1016\/j.antiviral.2022.105505","volume":"210","author":"L Hu","year":"2023","unstructured":"Hu\u00a0L et\u00a0al (2023) The race toward a\u00a0universal influenza vaccine: Front runners and the future directions. Antiviral Res 210:105505","journal-title":"Antiviral Res"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01640-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01640-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01640-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:02:40Z","timestamp":1704808960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01640-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01640-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"4 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Kwetkat: Forschungsunterst\u00fctzung: Forschungskolleg Geriatrie der Robert-Bosch-Stiftung, Fa. Pfizer Pharma GmbH; Vortragshonorare: Pfizer Pharma GmbH, Fa. MSD, FA. Novartis, Fa. Daiichi-Sankyo, Fa. Bristol-Myers Squibb, Fa. Sanofi-Pasteur, Fa. GlaxoSmithKline; Beratert\u00e4tigkeit: Fa. Seqirus, Pfizer Pharma GmbH, Sanofi-Pasteur, AstraZeneca; nicht-materielle Verbindung: Mitglied der AG RSV der STIKO. A.\u00a0Leischker: Vortragshonorar: GlaxoSmithKline, Sanofi-Pasteur; Beratert\u00e4tigkeit: GlaxoSmithKline, Pfizer Pharma GmbH, Sanofi-Pasteur; Reisekosten\u00fcbernahme: Pfizer Pharma GmbH. A.\u2011S.\u00a0Endres: Vortragshonorar von Pfizer Pharma GmbH. H.J.\u00a0Heppner: Forschungsunterst\u00fctzung: Forschungskolleg Geriatrie der Robert-Bosch-Stiftung, GB\u2011A Innovationsfonds; Vortragshonorare: Pfizer Pharma, Janssen Cilag, Tillotts Pharma, Bayerische Landes\u00e4rztekammer, AO Trauma Europe, GSK, ThermoFisherScience; Beratert\u00e4tigkeit: Pfizer Pharma, GSK-Pharma, Tillotts Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}